Attached files
| file | filename |
|---|---|
| EX-99.1 - WORLD HEART CORP | v204676_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
—————————————
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of
1934
Date of Report (Date of earliest event
reported) December 6, 2010
______________________________
WORLD HEART
CORPORATION
(Exact name of registrant as specified
in charter)
|
Delaware
|
000-28882
|
52-2247240
|
||
|
(State or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS Employer
Identification
No.)
|
|
4750 Wiley Post Way, Suite 120, Salt Lake City, UT
|
84116
|
|||
|
(Address of principal executive
offices)
|
(Zip
Code)
|
(801) 355-6255
Registrant’s telephone number, including
area code
Not Applicable
(Former name or former address, if
changed since last report)
______________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant
to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant
to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
Item 8.01.
Other Events.
On
December 6, 2010, World Heart Corporation announced that an
investigator-initiated study that includes patients who had received the Levacor
ventricular assist device (VAD) was the subject of a presentation in the
Emerging New Technologies Section at the Fifth European Mechanical Circulatory
Support Summit. Preliminary clinical data suggests that the Levacor
VAD does not cause acquired von Willebrand Factor (vWF) deficiency, a
condition
that is linked to serious bleeding disorders and that has been
associated with the use of current VADs.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit
99.1
|
Press
Release dated December 6, 2010
|
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, hereunto duly
authorized.
|
Date: December 6,
2010
|
||
|
WORLD HEART
CORPORATION
|
||
|
By:
|
/s/ Morgan R.
Brown
|
|
|
Name:
|
Morgan R.
Brown
|
|
|
Title:
|
Executive Vice President and Chief
Financial Officer
|